Targeting synthetic lethal interactions between Myc and the eIF4F complex impedes tumorigenesis
about
The Quest for Targets Executing MYC-Dependent Cell TransformationMYC, Metabolism, and CancerSynthetic lethal screens as a means to understand and treat MYC-driven cancersDrugging the addict: non-oncogene addiction as a target for cancer therapyInhibition of mTOR-kinase destabilizes MYCN and is a potential therapy for MYCN-dependent tumorsFlavaglines target primitive leukemia cells and enhance anti-leukemia drug activity.CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinomaSuppression of eukaryotic initiation factor 4E prevents chemotherapy-induced alopeciaThe spliceosome is a therapeutic vulnerability in MYC-driven cancer.A novel Bcr-Abl-mTOR-eIF4A axis regulates IRES-mediated translation of LEF-1Targeting the eIF4F translation initiation complex: a critical nexus for cancer developmentTaming of the beast: shaping Myc-dependent amplificationIdentification of a novel E-box binding pyrrole-imidazole polyamide inhibiting MYC-driven cell proliferation.Linking tumor mutations to drug responses via a quantitative chemical-genetic interaction map.Cell intrinsic and extrinsic activators of the unfolded protein response in cancer: Mechanisms and targets for therapymicroRNA-206 impairs c-Myc-driven cancer in a synthetic lethal manner by directly inhibiting MAP3K13.Targeting MYC in cancer therapy: RNA processing offers new opportunities.Myc and mTOR converge on a common node in protein synthesis control that confers synthetic lethality in Myc-driven cancersModifying chemotherapy response by targeted inhibition of eukaryotic initiation factor 4A.Tumor cell survival dependence on the DHX9 DExH-box helicaseMicroRNA-based screens for synthetic lethal interactions with c-MycCRISPR-Mediated Drug-Target Validation Reveals Selective Pharmacological Inhibition of the RNA Helicase, eIF4A.Stable RNA interference rules for silencing.Hippuristanol - A potent steroid inhibitor of eukaryotic initiation factor 4A.Developing anti-neoplastic biotherapeutics against eIF4F.Eukaryotic translation initiation factors and cancer.The mitochondrial translation machinery as a therapeutic target in Myc-driven lymphomasMelanoma Therapeutic Strategies that Select against Resistance by Exploiting MYC-Driven Evolutionary Convergence.Rocaglates as dual-targeting agents for experimental cerebral malaria.Hyperactivation of mTORC1 and mTORC2 by multiple oncogenic events causes addiction to eIF4E-dependent mRNA translation in T-cell leukemia.Pleiotropic antitumor effects of the pan-HDAC inhibitor ITF2357 against c-Myc-overexpressing human B-cell non-Hodgkin lymphomas.Inducible Genome Editing with Conditional CRISPR/Cas9 Mice.eIF4E-Dependent Translational Control: A Central Mechanism for Regulation of Pain Plasticity
P2860
Q26744579-A36B94D5-9F4F-4756-97B9-0C70BA18D5EBQ26783555-DB32359E-7F6B-450C-84AC-82FE365AE7CCQ27006010-B0C0FAAE-5A93-4676-B2D0-FB2E89D89B60Q28079559-525D1772-178C-4D1D-9D53-A803A9591B5BQ28817295-CD5128BA-DED2-4FC5-A573-7917F1BE168DQ34105627-84556D03-0745-459D-BFE7-67AF19E15F31Q34342934-051E5F9B-B911-4FAE-BE2D-ACD997C6552EQ34479333-7D3AFB88-CA69-487D-BFB7-EFE39938F241Q34492012-3A7578CC-83EC-44E3-8ED9-EEBF4C34068FQ34589167-DF53087F-BE74-41FC-997F-E4D42FA6B58DQ34988282-7F21F237-62B4-4F70-AA69-227A1781B477Q35235723-CE17C331-B00F-4F36-B039-23192F00EBD8Q35528327-2E77C836-E559-43D6-A481-3BE076D05CB9Q35531740-F43E1F7D-63C8-4FF5-AD6D-3929ACBFE891Q35912293-8D31AF5A-C8D7-4C9B-AEFE-BC60596130DFQ35937111-A2AE6C4F-21C0-42FE-98AF-E3BC116E940FQ36762189-1399C2EE-DB6E-473F-B2CC-B4DE47D11D3BQ37031640-7C9ED7A0-6504-4004-9782-B4D5562454ECQ37061433-5E463EBE-9129-493F-BF81-C0CCA26F8873Q37256287-D16CD795-5325-41BC-A883-CB6FEE12AC34Q37495218-2CC4CF7E-D312-4558-8FF8-2F5C65D6DDEFQ37649874-0ED9CEB7-711E-4F2A-9DC7-1BE10FA969B7Q38173633-BD2319CA-360E-4C39-A5FF-D740EC43E81CQ38874189-A8870C59-BFF8-43CF-8124-A939BFF1EE71Q39048156-319041FC-BFDE-4A6B-B0E1-98399C88C545Q39400409-6D1D1C9C-EB34-41FE-9D92-9BE48C306BDAQ42124282-BCAF396F-8CD0-495A-998C-071DD89E20E1Q47143892-1D2AB2AD-992B-4E22-9C7B-E02669C12F20Q49790353-D6C7CF17-0F46-42D8-8B1D-CFB13DE5BD57Q51051812-4AAB5F98-F071-4844-A69E-57264F9135EFQ51747268-BC1FF067-ECFF-40D3-A769-CA6E33CF29DFQ52430693-B473E00A-8E33-4049-AD38-18153ADC98DAQ59136306-E593B2EF-F103-4BE1-969B-955189F75442
P2860
Targeting synthetic lethal interactions between Myc and the eIF4F complex impedes tumorigenesis
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Targeting synthetic lethal int ...... complex impedes tumorigenesis
@ast
Targeting synthetic lethal int ...... complex impedes tumorigenesis
@en
type
label
Targeting synthetic lethal int ...... complex impedes tumorigenesis
@ast
Targeting synthetic lethal int ...... complex impedes tumorigenesis
@en
prefLabel
Targeting synthetic lethal int ...... complex impedes tumorigenesis
@ast
Targeting synthetic lethal int ...... complex impedes tumorigenesis
@en
P2093
P2860
P1433
P1476
Targeting synthetic lethal int ...... complex impedes tumorigenesis
@en
P2093
Chen-Ju Lin
Jerry Pelletier
John A Porco
Prem K Premsrirut
Scott W Lowe
Yoshitaka Hippo
Zeina Nasr
P2860
P304
P356
10.1016/J.CELREP.2012.02.010
P577
2012-04-01T00:00:00Z